Company: GANX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001558370-25-005829
Chunk: 47

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 47
---
, Mr. Mack would have been eligible to receive (x) (i) a cash severance equal to twelve (12) months of base salary; (ii) if Mr. Mack timely elected to receive continued coverage under our group health care plan pursuant to COBRA or applicable state continuation coverage laws, then he would have been eligible to receive payment of the employer portion of his COBRA premiums for the twelve (12) month period after the termination; (iii) an annual cash bonus equal to his pro-rated annual target bonus opportunity for the year in which the termination of employment occurred, and (iv) an annual cash bonus equal to his annual target bonus opportunity that would have accrued during the twelve (12) month period after the termination of employment occurs; and (y) accelerated vesting of 100% of any then-unvested stock awards.

<div align='center'>32</div>

#### Gianluca Fuggetta
In connection with his appointment as our Principal Financial Officer, we entered into an employment agreement with Mr. Fuggetta, effective January 1, 2025, whereby Mr. Fuggetta is entitled to receive an annual base salary of CHF 200,000 and is eligible to receive, as determined by the Board in its sole discretion, an annual incentive cash bonus with a target payout of 30% of his annual base salary. Further, if we terminate Mr. Fuggetta without good cause, we will pay to Mr. Fuggetta severance equal to six months base salary. If we terminate Mr. Fuggetta within 12 months following a change in control without good cause, the gross severance will equal to 12 months of his annual base salary.

#### Matthias Alder
In connection with his appointment as President and Chief Executive Officer, we had entered into an amended and restated employment agreement with Mr. Alder (the “Alder Employment Agreement”) dated September 20, 2022 (the “Effective Date”).

Pursuant to the Alder Employment Agreement, Mr. Alder was entitled to (i) an annualized base salary of $525,000 and (ii) an annual incentive cash bonus with a target of 50% of his annual base salary, as determined by the Board in its sole discretion. Pursuant to the Alder Employment Agreement, the Board approved the grant to Mr. Alder of an option to purchase up to 60,900 shares of our common stock at an exercise price